Data on BAY 59-7939 at the XXth Congress of the International Society on Thrombosis & Haemostasis (ISTH)

August 6 - 12, 2005 in Sydney, Australia


August 8, 2005:
IR Conference Call - ISTH Review 2005

The audio recording of this event is no longer available.

Background Information
Thromboembolic disorders: A major cause of morbidity and mortalityDownload ( PDF, 248 KB ) collect
Current anticoagulant therapiesDownload ( PDF, 241 KB ) collect
Coagulation PathwayDownload ( PDF, 81 KB ) collect
GlossaryDownload ( PDF, 103 KB ) collect

ISTH 2005 Abstracts on BAY 59-7939

An Oral, Direct Factor Xa Inhibitor – BAY 59-7939 – For Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: A Dose-ranging Study

Prevention Of Venous Thromboembolism With An Oral, Direct Factor Xa Inhibitor – BAY 59-7939 – In Elective Hip Replacement: A Dose-Ranging Study

Aspirin Has No Effect on the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BAY 59-7939 – an Oral, Direct Factor Xa Inhibitor

Interaction Of BAY 59-7939 – A Novel, Oral, Direct Factor Xa Inhibitor – With Antiplatelet Agents: Monitoring And Therapeutic Applications

Effect Of BAY 59-7939 – A Novel, Oral, Direct Factor Xa Inhibitor – on Clot-Bound Factor Xa Activity In Vitro

Effect of Enoxaparin on the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BAY 59-7939 – an Oral, Direct, Factor Xa Inhibitor

The Oral, Direct Factor Xa Inhibitor – BAY 59-7939 – Inhibits Thrombin Generation In Vitro After Tissue Factor Pathway Activation

Antithrombotic Mechanism of Action of BAY 59-7939 – a Novel, Oral, Direct Factor Xa Inhibitor

Comparison of the Anticoagulant Properties of BAY 59-7939 – an Oral, Direct Factor Xa Inhibitor – with Fondaparinux and Enoxaparin

Last updated: January 13, 2014 Copyright © Bayer AG